Relapse after allo-SCT for AML carries very poor prognosis. Second allo-SCT, although curative, is not an appropriate treatment option for a large number of relapsing patients (only 2-20% patients receive a second allo-SCT), and efforts to increase the number of patients who may benefit from a second allo-SCT are ongoing. In addition, understanding the varied biological processes that are operative in disease relapse has encouraged the development of novel therapies, and could be beneficial to patients who are currently managed conservatively with supportive care for relapsed disease. Incorporating novel combinations of drugs with immunomodulation, although theoretically attractive, should be tested in the setting of clinical trials. In this review, we discuss the currently available approaches for relapsed AML after allo-SCT.
Introduction
Treatment outcome for patients with AML has improved substantially over the past decade. CR rates after chemotherapy range from 60 to 80%, and long-term survival is achieved in about 30-60% of patients after transplantation. Unfortunately, relapse occurs in 20-70% of patients after allo-SCT. The risk of relapse depends on several factors, for example, age of the patients, disease status pre-SCT, AML subtypes (primary vs secondary), cytogenetic and molecular markers, type of conditioning regimen, stem cell source and so on. [1] [2] [3] [4] [5] [6] Disease relapse is the most common cause of treatment failure after allo-SCT for advanced myeloid malignancies, and generally carries a poor prognosis with a median survival of 3-4 months without active treatment. [7] [8] [9] [10] [11] [12] [13] Although donor lymphocyte infusion (DLI) can induce responses in a substantial proportion of patients with CML, patients with AML who relapse after allo-SCT rarely benefit from this strategy. A number of patients with good performance status who achieve a second remission may be considered for a second allo-SCT. Second transplants have been increasingly used in recent years, as more patients are receiving unrelated donor and nonmyeloablative conditioning transplantation. Most reported studies are retrospective and limited by the small number and heterogeneity of patients from CML-chronic phase to acute leukemias (both myeloid and lymphoid). It is likely that factors governing the outcome after second transplant will be different in AML compared with other hematological malignancies. Table 1 summarizes the results of recently published studies using second allo-SCT for relapsed AML.
Second allo-SCT
A second allo-SCT is offered to only a minority of patients in most series (2-20%). 11, 14, 15 Both, patient and disease-related factors have a role while considering further therapy for relapsed disease after an allo-SCT, but the identification of factors influencing survival and relapse rates and the determination of patient groups who best respond to the procedure is difficult. Moreover, disease relapse remains the major cause of treatment failure after a second allo-SCT.
Prognostic factors affecting outcome after second allo-SCT Although age, disease status and conditioning regimen are important, duration of remission after first transplantation seems to be the most important determinant of outcome. The time interval between the first allo-SCT and relapse has been described as an important prognostic factor by several investigators. [10] [11] [12] [13] [14] 16 In a study by Hosing et al., 12 the subset of patients who received a second allo-SCT for relapse within a year of the first transplant had a worse outcome. Similarly, data from CIBMTR (Center for International Blood and Marrow Transplant Research) have shown that in patients who relapse within 6 months of the first allo-SCT, the probability of leukemia-free survival and relapse is 7 and 77%, respectively, compared with 28 and 59% in patients who relapse more than 6 months after the first allo-SCT. 17 Therefore, one can argue that there is little benefit in subjecting patients with post transplant remission durations of o6 months to a second aggressive procedure. These patients should be offered supportive care only or considered for clinical trials using novel combination approaches.
Other factors reported to be associated with outcome after second allo-SCT are remission status at the time of second transplant; 12, 13, 17, 18 using a female donor; 19 development of GVHD after the second allo-SCT; 20, 21 and the source of stem cells. 22 Leukemia burden at the time of first transplantation is considered to be a bad prognostic factor. [10] [11] [12] [13] 17, 18 However, in most series, the interval between the first transplantation and relapse remains the most significant factor in determining the outcome of a second transplantation. [10] [11] [12] [13] 17, 20, 21, [23] [24] [25] [26] First allo-SCT: reduced-intensity conditioning vs myeloablative SCT and outcome after second allo-SCT A number of studies have shown that the management and prognosis of patients who relapse after reduced-intensity conditioning (RIC) allo-SCT is different compared with patients relapsing after myeloablative SCT (MST). 8, 27 Pollyea et al. 8 reported an overall CR rate of 61% in their series of patients who received an induction chemotherapy followed by a second allo-SCT for relapse after RIC, which is highly encouraging. Over half of the patients in their study were eligible to receive a second allo-SCT (compared with 2-20% after MST regimen); many achieved or maintained a CR, with a low TRM after the second allo-SCT. Despite the short median time from the first allo-SCT to relapse and the relatively older age, patients tolerated re-induction chemotherapy well with a low TRM for the second transplant. 3, 8, 9, 28, 29 However, the reduced TRM did not translate into a better long-term outcome. Relapse remains a problem and about 70% of patients ultimately succumbed to disease progression, a finding consistent with outcomes for relapse after MST regimens. 8, 9, 13, 14, [28] [29] [30] TRM associated with second allo-SCT The toxicity of the conditioning regimen of second allo-SCT is a significant concern, especially if an MST regimen is employed or in patients receiving re-induction chemotherapy before second allo-SCT. In the study by Hosing et al., 12 the TRM after the second allo-SCT was 36%. Radich et al. 31 reported a 1-year TRM of 45% and a 1-year leukemia-free survival of only 14% after the second allo-SCT. Similarly, CIBMTR data showed a 2-year TRM of 41% after a second SCT, which was 3.9 times higher in patients receiving a second transplant within 6 months of the first SCT. 17 Age correlated with TRM, treatment failure and overall mortality. Details of TRM with different conditioning regimen are summarized in Table 1 .
Reduced-intensity vs myeloablative conditioning for a second allo-SCT The use of RIC regimens for second allograft may extend the applicability of second allo-SCT in the relapse setting. 11, 13, 14, 32 However, the risk of relapse was reported to be higher after RIC regimens for second allo-SCT. Eapen et al.
11 reported increased relapse rates in patients who received RIC regimens for the second allo-SCT. This was independent of the duration of remission after the first transplant and the disease status at the second transplant, suggesting that dose intensity may be important in this setting. In this study, patients who received a reducedintensity preparative regimen for the second transplant had a similar survival compared with those who received MST conditioning. Some reports suggest that conditioning regimens with TBI may lower mortality in patients with acute leukemia after the second transplantation. 13, 20 These data should be interpreted with caution because of lack of homogeneity of conditioning regimens, as well as because of probable bias in patient selection and limited details of pre-SCT disease status.
The reduced-intensity conditioning allo-SCT approach combined with re-induction chemotherapy using fludarabine in combination with high-dose cytarabine (Ara C), idarubicin and G-CSF (FLAG-Ida), or similar regimens, and peripheral blood CD34 þ cells as the source of stem cells (PBSCT) has been shown to be effective in sustained engraftment with reports of prolonged remission. FLAGIda (can be modified to FLAG in those with poor cardiac function) provides good cytoreduction and strong immunosuppression that favors the engraftment of donorderived allo-reactive T cells. 32 The support with stem cells ensures prompt hematopoietic recovery that further alleviates hematological toxicities, and avoids the lethal aplasia associated with DLI alone. Compared with standard myeloablative conditioning protocols, the regimen is relatively well tolerated and safe. 8, [32] [33] [34] [35] [36] [37] Same donor vs different donor for second allo-SCT There are no convincing data to support an advantage for the selection of a different donor over the original donor for the second transplant. The published data are limited by the small number of case series reported in the literature.
11, 38 Hosing et al. 12 observed a trend toward improved survival when a different donor was selected for the second allo-SCT; however; owing to the small number of patients, this difference did not reach statistical significance. A total of 10 patients has been reported in the literature to have received two unrelated donor transplants. 11, 12, 38 At the time of reporting all had died. There were three deaths due to disease relapse and seven died because of transplant-related causes. On the basis of this report, it is not justifiable to recommend a second unrelated donor transplant to patients who have relapsed after a first unrelated donor transplant. Eapen et al. 11 found no evidence supporting the use of a different HLA-identical donor for a subsequent transplant. The assumption that using a different matchedrelated donor increases the likelihood of GVHD and subsequent GVL effect is not supported by available data.
The risks of relapse and mortality were similar whether or not a different donor was used.
BM vs PBSC graft for second allo-SCT Although some studies in adults report survival advantages after PBSCT for advanced leukemia, others report a lower risk of relapse using BM for the second allo-SCT. 13, 22 Eapen et al. 11 did not observe an influence of the graft source on relapse or mortality, whereas Russell et al. 22 reported an advantage for using PBSCT as the source of stem cells in 10 patients undergoing a second allo-SCT for leukemia. It is possible that the larger lymphocyte dose in PBSCT preparation might confer an enhanced GVL effect compared with BMT, 39 although in a study by Bosi et al., 13 the advantage of PBSCT on leukemia-free survival was not confirmed. The small number of patients in most studies limits our ability to draw any conclusions from the available and mostly retrospective data, but it seems that PBSCT has some advantage resulting in early hematopoietic recovery in these heavily pre-treated patients receiving second allografts. Furthermore, the higher lymphocyte dose might enhance the GVL effect for this high-risk group of patients. There are no available data on the TRM rates of PBSCT compared with BM as the source of stem cells for the second allo-SCT. Table 2 , summarizes the results of recently published studies using DLI for relapsed AML.
DLI for relapsed disease
Results of DLI in the treatment of relapse in advanced myeloid malignancies after allo-SCT are disappointing; only 10-20% of patients achieve CR and remission is usually brief. [40] [41] [42] [43] [44] Rapidly evolving disease seems to be less responsive to immunotherapy, although it is possible that this lack of efficacy may be due to the leukemia outpacing the ability of the T cells to control the disease. It will be important to identify, in advance, which patients may benefit from the procedure. Patients with favorable cytogenetics, those achieving a hematological remission before DLI or patients with a lower tumor burden at the time of relapse, are more likely to benefit from this procedure. EBMT (European Group for Blood and Marrow Transplantation) 45 data have shown that responses to DLI are only achieved in a minority of patients with AML. Moreover, acute and chronic GVHD and infections from marrow aplasia and/or immunosuppressive therapy after DLI are associated with substantial morbidity and mortality. 43, 44 The timing of DLI is also very important. A number of studies have shown that DLI given post-chemotherapy during the lymphopenia phase (for example, after fludarabine-based chemotherapy) or as consolidation of a chemotherapy-induced remission will result in improved outcome. 46, 47 Recent prospective trials have reported CR rates of 47-63% with OS rates of 19-31% at 2 years in patients with relapsed advanced myeloid malignancies who were treated with induction chemotherapy, followed 7-14 days later by G-CSF-mobilized PBMCs as the source of DLI. [41] [42] [43] [44] 48 For patients who achieved CR after chemotherapy and DLI, the 1-year survival rate was B40-50% compared with a 1-year OS of 0-5% in non-responders. Therefore, remission induction with good disease control is an important predictor of long-term outcome after DLI, as observed after second allo-SCT. The most important predictor of survival using this approach is time from transplant to relapse; the 1-year survival for patients receiving DLI for relapse more than 6 months after SCT was about 50% compared with 0-10% for patients relapsing less than 6 months from transplant. [41] [42] [43] [44] 48 Thus, for the group of patients who relapse within 6 months after SCT, novel manipulations of DLI or other therapy should be considered.
Future work should focus on unifying the definition of the components and cell doses of DLI, defining a dose/ efficacy and a dose/toxicity relationship and developing ways to improve the efficacy of DLI either through graft manipulation or host conditioning (that is, pre DLI lymphodepletion 46 ). Interestingly, in a number of patients, the relapse post-DLI was characterized by extramedullary disease in the absence of marrow involvement. 36, 43, 44, [48] [49] [50] [51] [52] This observation suggests that the disease can recur either in a sanctuary site or in a clone of cells with a surface complement of proteins that allow escape from immunological recognition or attack. This observation calls into question the activity of GVL in the extramedullary site. Extramedullary relapse may also be an early indicator of impending marrow relapse.
Unrelated DLI for relapsed disease Unrelated DLI can carry an increased risk of significant GVHD, and it is not known whether unrelated DLI can provide worse, similar or even enhanced GVL activity compared with matched-related DLI. Two large registry studies suggested that unrelated DLI and related DLI result in similar outcomes, but only a small number of patients were included. 40, 45 Similarly, a study of DLI for relapsed CML did not show a significant difference in outcome using matched sibling or unrelated DLI. 53 In a recent retrospective analysis of 23 patients with relapsed AML who received DLI from a matched-unrelated donor, CR was achieved in 42% of patients. The incidence of grade II-IV acute GVHD was 25% and chronic GVHD occurred in 41% of patients. The estimated probability of disease-free survival at 1 year after CR was 23%. In this study, there was no association of mononuclear cell dose with GVHD, response, survival or disease-free survival. A longer time interval from transplant to relapse and transplant to unrelated DLI were the only factors associated with improved survival and disease-free survival, respectively. 54 It should be noted that comparing outcome data in patients with leukemia receiving DLI from unrelated or related donors is difficult, largely because of the small numbers of patients studied, the relatively short follow-up in most studies and the retrospective nature of the data. Nevertheless, the CR rates for recipients of unrelated DLI for advanced myeloid leukemia seem at least similar if not higher than rates reported in related DLI studies.
Disease burden reduction before second allo-SCT or DLI Tables 1 and 2 summarize the results of recently published studies using cytoreduction before second transplant and/ or DLI for relapsed disease after allo-SCT.
Chemo-allo-SCT
The preferred approach by most clinicians is to offer a second allo-SCT only to patients who achieve remission after re-induction chemotherapy. Mrsic et al. 17 and Kishi et al. 18 observed a significantly better leukemia-free survival in patients receiving a second allo-SCT in remission compared with patients who had evidence of residual disease prior to the second allograft.
Small case series have shown successful salvage with FLAG-Ida or similar combination chemotherapy followed by RIC allograft. [32] [33] [34] The dose of chemotherapy should be adjusted depending on the timing of the post transplant relapse, as in the majority of patients, the tolerance to chemotherapy in the early post-SCT period is very poor and likely to be associated with severe complications, such as delayed hematological recovery and tissue damage, for example, severe GVHD. Another regimen used in this setting, MEC (mitoxantrone, etoposide and cytarabine) followed by G-CSF-mobilized PBSCT, was reported to induce CR in 70% of patients with long-term survival in a selected group of B35% (Table 1) .
34,55
Chemo-DLI A major factor limiting the response to DLI alone in AML may be the rapid proliferation rate of leukemic cells coupled with the high leukemic cell burden at the time of relapse. As the GVL effect of DLI typically requires several weeks or months to become clinically apparent, in patients with rapidly advancing disease such as AML, it is reasonable to attempt cytoreductive chemotherapy before DLI to allow time for the development of the GVL effect.
Investigators have shown successful use of cytarabine, idarubicin and etoposide, and 2 days later, G-CSFmobilized DLI. 36 No GVHD prophylaxis was given in this study. CR was achieved in 85% of patients at a median of 27 days after DLI, and at a median follow-up of about 11 months, 6 of 8 AML patients remained alive. Hematological recovery after chemotherapy and DLI was rapid; however, grade III-IV acute GVHD occurred in almost half, suggesting the need for low-dose GVHD prophylaxis.
Comparing results of chemo-DLI with a second allo-SCT, 13, 15, 17, 20, 23, 42, 48 TRM seems to be lower in the former (20-25 vs 40-50%), although long-term survival was reported to be similar in both approaches (20-35 vs 10-35%). However, it should be noted that most patients in the chemo-DLI group had an untreated relapse, whereas patients in the second allo-SCT group were highly selected (only 2-20% of relapsing patients actually receive a second allo-SCT) and the majority had achieved some sort of remission induced by chemotherapy before the second allo-SCT. Therefore, the outcome of the chemo-DLI approach seems to compare favorably with a second allo-transplant. 48 In patients with remission duration of 6 months or longer after the first allo-SCT, the 1-year OS after chemo-DLI is in the range of 50-55%, suggesting that this approach may be of benefit in patients who are not eligible for a second allograft with either RIC or MST conditioning. In contrast, patients with post-SCT remission duration of less than 6 months are unlikely to benefit from chemo-DLI and should be considered for other investigational therapies in the context of well-designed clinical trials.
The major risk of the chemo-DLI approach is the high incidence of GVHD and GVHD-related deaths. This may be because of the fact that in most studies, GVHD prophylaxis was not used to avoid the possibility of increasing the risk of relapse due to a reduction in the GVL effect. Another factor possibly associated with the high incidence of GVHD may be related to cumulative tissue damage caused by chemotherapy that may be further exacerbated by the early application of DLI after chemotherapy. 46, 48, 55 Incorporating novel drug combinations with allo-SCT or DLI Studies have shown that, gemtuzumab (GO) therapy is effective for patients with extramedullary relapse, which is considered a sanctuary site for the GVL effect. 56, 57 The selectivity of GO for CD33 þ blast and progenitor hematopoietic cells makes it an attractive agent to use in post transplant relapse. GO is a recombinant humanized MoAb that targets the CD33 Ag that is expressed in more than 90% of myeloid malignancies.
Recently, Tamai et al. 57 used GO followed by DLI in a patient with post-allo-SCT relapse with prolonged remission, and the combination of GO and chemotherapy seems to be well tolerated. 58 Further studies are required to determine the effects of GO followed by DLI or GO with a second allo-SCT for advanced myeloid relapse after allo-SCT.
Hypomethylating agents have been shown to be effective in the treatment of relapsed AML after allo-SCT. 19, 59 Santourlidis et al. 60 reported that treatment with DNAdemethylating agents results in rapid and stable induction of transcription and cell surface expression of formerly unexpressed KIRs (killer Ig-like receptors) in natural killer cells that are involved in the specific recognition of leukemic target cells and are able to generate a GVL effect. Furthermore, treatment with low-dose azacytidine is associated with only marginal non-hematopoietic toxicity. Future studies are required to study the role of hypomethylating agents alone or in combination with low-dose GO, DLI or second allo-SCT for relapsed AML.
Clofarabine is another promising drug that needs to be investigated in conjunction with DLI or a second allo-SCT for relapsed disease. Clofarabine has been shown to be effective in refractory AML and well tolerated even in elderly patients. 61 Studies have shown synergistic activities with cytarabine and CY. Similarly, the combination of DNR, clofarabine and GO was found to be effective and feasible in a pilot study of patients who were all older than 60 years. Additional data have also shown this novel drug to have an effective immunosuppressive property, making it suitable in the transplant setting.
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Withdrawal of immunosuppression
If relapse occurs while patients are still receiving immunosuppressive therapy for GVHD, rarely remission may follow the withdrawal of immunosuppression (especially in patients with minimal disease, mainly in CML); however, this may increase the risk of uncontrolled GVHD.
This approach is in many respects a double-edged sword, as most patients with relapsed advanced myeloid leukemia will not respond to withdrawal of immunosuppressive therapy alone. Moreover, treatment for relapsed disease (drugs, DLI) may further complicate the management of the patient by increasing the severity of GVHD. This approach should only be reserved for patients with early relapse or in molecular relapse in the absence of active GVHD.
Cost factor
The cost of allo-SCT remains very high and the inpatient cost accounts for most of the total expenditure. The use of unrelated donors and advanced disease status have been shown to be associated with higher costs. 65, 66 Severe toxicity, especially in patients with early relapse with extensive tissue damage after induction chemotherapy and severe GVHD after DLI or second allo-SCT, will escalate costs further. Messori et al. 65 recently conducted an analysis of published survival data in acute leukemia patients who experienced relapse after receiving allo-SCT to evaluate the cost-effectiveness of a second allo-SCT in comparison with conventional chemotherapy. It is possible that if the rate of complications can be reduced by a riskadapted approach, the incorporation of newer drugs, a combination approach of cytoreductive chemotherapy for disease control and fewer regimen-related toxicities, this cost can be significantly reduced and outcome may also be improved.
In summary, treatment options for patients with AML who relapse early after allo-SCT are limited with extremely poor prognosis, especially in patients relapsing early post transplant. Very few patients are eligible for second allo-SCT and results with DLI alone are poor, especially in the presence of active disease. However, from the limited data available, results seem to be better in patients receiving second allo-SCT using RIC regimen who are in CR. Large multicenter studies are needed to determine the best treatment options for patients with AML who relapse after allo-SCT, as it is difficult to draw firm conclusions from the published small retrospective case series. Until more data becomes available from prospective clinical trials, we propose that for selected patients with AML relapsing after allo-SCT, induction of CR or minimal leukemia burden followed by DLI and/or a second allograft with the addition of some form of maintenance chemotherapy may offer the best chance of long-term survival.
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